US SB1128 | 2013-2014 | 113th Congress
Status
Spectrum: Bipartisan Bill
Status: Introduced on June 11 2013 - 25% progression, died in committee
Action: 2013-06-11 - Read twice and referred to the Committee on Finance.
Pending: Senate Finance Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on June 11 2013 - 25% progression, died in committee
Action: 2013-06-11 - Read twice and referred to the Committee on Finance.
Pending: Senate Finance Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Preserving Access to Orphan Drugs Act of 2013 - Amends the Patient Protection and Affordable Care Act (PPACA) to exclude any drug or biological product which is approved or licensed by the Food and Drug Administration (FDA) for marketing solely for one or more rare diseases or conditions (orphan drug) from the annual fee on manufacturers or importers with branded prescription drug sales exceeding $5 million. Makes this Act effective as if included in PPACA.
Title
Preserving Access to Orphan Drugs Act of 2013
Sponsors
| Sen. Pat Toomey [R-PA] | Sen. Thomas Carper [D-DE] | Sen. Robert Casey [D-PA] | Sen. Mike Crapo [R-ID] |
| Sen. Christopher Murphy [D-CT] | Sen. Marco Rubio [R-FL] | Sen. Roger Wicker [R-MS] |
History
| Date | Chamber | Action |
|---|---|---|
| 2013-06-11 | Senate | Read twice and referred to the Committee on Finance. |
Same As/Similar To
HB2315 (Same As) 2013-07-25 - Referred to House Energy and Commerce
Subjects
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/113th-congress/senate-bill/1128/all-info |
| Text | https://www.congress.gov/113/bills/s1128/BILLS-113s1128is.pdf |
